Title: 2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018 Document date: 2018_10_25
ID: 60ceejq1_234
Snippet: In conclusion, these preliminary results suggest that rTMS is a safe procedure that might decrease median MSF and MSDF and result in an improvement in seizure management in dogs with drug-resistant epilepsy. However, a larger number of dogs is required for both groups before definitive conclusions can be made. Using a non-randomized cross-over design, nine clinically healthy cats received a single dose of 500 mg of approved ER-LEV PO. Thirteen bl.....
Document: In conclusion, these preliminary results suggest that rTMS is a safe procedure that might decrease median MSF and MSDF and result in an improvement in seizure management in dogs with drug-resistant epilepsy. However, a larger number of dogs is required for both groups before definitive conclusions can be made. Using a non-randomized cross-over design, nine clinically healthy cats received a single dose of 500 mg of approved ER-LEV PO. Thirteen blood and 1-2 CSF samples were collected over 24 hours. After a one-week washout period, the study was repeated with a single oral dose of 500 mg compounded ER-LEV. LEV was quantitated by immunoassay. Plasma and pooled CSF LEV concentrations versus time data were subjected to noncompartmental pharmacokinetic analysis and data were compared between formulations using a paired t-test.
Search related documents:
Co phrase search for related documents- cross design and non randomized cross design: 1, 2, 3
- cross design and oral dose: 1, 2, 3
- cross design and pharmacokinetic analysis: 1, 2, 3
- cross design and safe procedure: 1
- cross design and single dose: 1, 2
- cross design and washout period: 1, 2, 3
- cross design and week washout period: 1
Co phrase search for related documents, hyperlinks ordered by date